Overview

CJC-1295 and tesamorelin are both synthetic analogues of growth hormone-releasing hormone (GHRH), designed to act for longer than native GHRH. No source checked compares them head to head, so this page sets the two published records side by side. It describes clinical research on licensed or investigational compounds. Stackpure products are laboratory research reagents and are not for human use.

Side by side

PointDetailSource
DesignCJC-1295 is a long-acting GHRH analogue that binds albumin after injection (Ionescu 2006). Tesamorelin is described in its trials as GHRH(1-44) (Falutz 2010).Ionescu 2006, Falutz 2010
Half-life and exposureCJC-1295: estimated half-life 5.8 to 8.1 days; IGF-I raised 1.5- to 3-fold for 9 to 11 days after one dose. Tesamorelin: daily 2 mg subcutaneous dosing in the phase 3 trials.Teichman 2006, Falutz 2010
Population studiedCJC-1295: healthy adults aged 21 to 61. Tesamorelin: 806 HIV-infected patients with excess abdominal fat in the pooled analysis.Teichman 2006, Falutz 2010
Key resultCJC-1295: GH up 2- to 10-fold for 6+ days with pulsatility preserved. Tesamorelin: visceral fat fell 24 cm2 vs a rise of 2 cm2 with placebo; IGF-I rose 108 ng/mL.Teichman 2006, Ionescu 2006, Falutz 2010
Regulatory status describedTesamorelin approved for HIV lipodystrophy. CJC-1295: not described as approved in the sources checked.Grunfeld 2011

Read each in full

See What Is CJC-1295?, What Is Tesamorelin? and tesamorelin vs sermorelin.

What the sources do not show

  • No head-to-head study of CJC-1295 and tesamorelin appears in the sources checked.
  • The two were studied in different populations (healthy adults versus adults with HIV lipodystrophy), so their results cannot be compared directly.
  • No source checked reports long-term safety data for CJC-1295.
  • Stackpure does not give dosing guidance.

Related research products and tools

Frequently Asked Questions

What is the difference between CJC-1295 and tesamorelin?

Both are GHRH analogues. CJC-1295 is long-acting and was studied in healthy adults, while tesamorelin was studied in adults with HIV lipodystrophy (Teichman 2006, Falutz 2010).

Have they been compared directly?

Not in the sources checked.

Key References

  • Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PubMed 16352683
  • Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. 2006. PubMed 17018654
  • Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010. PubMed 20554713
  • Grunfeld C, et al. Tesamorelin. Nat Rev Drug Discov. 2011. PubMed 21283099

For research use only. Not for human consumption.